Overview
Werewolf Therapeutics Q3 net loss narrows slightly from last year
Research and development expenses decreased in Q3 compared to same period in 2024
Company received Fast Track Designation for WTX-124 from the US FDA
Outlook
Werewolf to update on WTX-124 Phase 1/1b trial in Q4 2025
Company plans WTX-330 trial update in Q4 2025
Werewolf to nominate WTX-1011 target by year-end 2025
Result Drivers
Research and development expenses were $11.6 million for the third quarter of 2025, compared to $12.5 million for the same period in 2024
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$16.37 mln
Q3 Basic EPS
-$0.36
Q3 Operating Expenses
$15.72 mln
Q3 Operating Income
-$15.72 mln
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Werewolf Therapeutics Inc is $7.00, about 81.3% above its November 3 closing price of $1.31
Press Release: ID:nGNX1PFY0X
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
